What happens in the blood of post-COVID patients? And can the presence of specific substances in the bloodstream assist in better diagnosis and treatment of post-COVID? To gain a better understanding of these topics, RIVM is launching a study on bio...

Many people who report having long-term COVID-19 symptoms are unable to fully participate in society. This is a key finding from the twelfth quarterly research update from the Network for Health Research in Disasters (GOR Network).

The new COVID-19 vaccination round will start on 16 September 2024. For people who are at higher risk, the COVID-19 vaccination offers more effective protection against hospital admission or death due to COVID-19.

Starting today, people with post-COVID can sign up to take part in scientific research. They can register through the national portal at postcovidonderzoek.nl, which is part of the Post-COVID Network Netherlands.

Monitoring well-being from the outset and throughout the duration of a pandemic, health emergency or other crisis provides helpful input in making policy choices.

The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.

People who live in areas with poor air quality are more likely to become infected with SARS-CoV-2. Moreover, the symptoms of COVID-19 are more severe, leading to more hospitalisations and deaths. This is the outcome of a study conducted by RIVM, Utrecht University, Wageningen University & Research and the Netherlands Municipal Public Health Services and Medical Assistance in Accidents and Disasters.

In the 2023 autumn round, more than 2,731,000 people in the Netherlands received a COVID-19 vaccination. Vaccination coverage for people over 60 is currently 50.5%. Vaccination coverage varies by age group and region. COVID-19 vaccination was available until 22 December 2023.

Booster vaccinations reduced the risk of dying from COVID-19 in 2022. The risk of death from other causes was also lower for people who had a booster jab than for people without a booster jab. These findings are from research by RIVM.